Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during hepatitis C virus genotype 1 triple therapy.

Trial Profile

Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during hepatitis C virus genotype 1 triple therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2016

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top